These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 8689422)

  • 1. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma.
    Triozzi PL; Walker MJ; Pellegrini AE; Dayton MA
    Cancer Invest; 1996; 14(4):293-8. PubMed ID: 8689422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Strojan P; Rudolf Z
    Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.
    Fierlbeck G; Schreiner T; Rassner G
    Cancer Immunol Immunother; 1995 Mar; 40(3):157-64. PubMed ID: 7728774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
    Hanson DS; Leggette CT
    Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
    [No Abstract]   [Full Text] [Related]  

  • 8. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma.
    Rosenthal MA; Oratz R
    Am J Clin Oncol; 1998 Aug; 21(4):352-4. PubMed ID: 9708632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
    Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
    Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
    Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
    Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
    Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G
    Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in melanoma therapy.
    Johnson TM; Yahanda AM; Chang AE; Fader DJ; Sondak VK
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):731-41. PubMed ID: 9591818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
    Lane AM; Egan KM; Harmon D; Holbrook A; Munzenrider JE; Gragoudas ES
    Ophthalmology; 2009 Nov; 116(11):2206-12. PubMed ID: 19744725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
    Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
    Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata accuminata.
    Cardamakis EK; Kotoulas IG; Dimopoulos DP; Stathopoulos EN; Michopoulos JT; Tzingounis VA
    Arch Gynecol Obstet; 1996; 258(1):35-41. PubMed ID: 8789431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo induction of the interferon-stimulated protein 2'5'-oligoadenylate synthetase in tumor and peripheral blood cells during IFN-alpha treatment of metastatic melanoma.
    Grandér D; Sangfelt O; Skoog L; Hansson J
    J Interferon Cytokine Res; 1998 Sep; 18(9):691-5. PubMed ID: 9781807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
    J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.